Predictive proteomic biomarkers for inflammatory bowel disease-associated cancer: where are we now in the era of the next generation proteomics?
Predictive proteomic biomarkers for inflammatory bowel disease-associated cancer: where are we now in the era of the next generation proteomics?
复制标题
DOI：
10.3748/wjg.v20.i37.13466
复制
发表时间：
2014-10
影响因子：
4.3
通讯作者：
Jong‐Min Park;Na-Young Han;Youngmin Han;M. Chung;H. Lee;K. Ko;Eun-Hee Kim;K. Hahm
中科院分区：
文献类型：
--
作者：
Jong‐Min Park;Na-Young Han;Youngmin Han;M. Chung;H. Lee;K. Ko;Eun-Hee Kim;K. Hahm
基因组医学的最新进展开辟了定制药物的可能性，最终可能取代传统的“一刀切”方法来治疗炎症性肠病（IBD）。除了探索宿主和微生物（称为微生物组）之间的相互作用外，正在研究在即将到来的IBD治疗个性化医学时代中可以为个体量身定制的各种策略。这些包括对有患IBD风险的患者进行及时的基因组筛查，在被诊断患有IBD的患者中对IBD亚型进行分子鉴别的效用，以及发现蛋白质组生物标志物以诊断或预测癌症风险。宿主遗传因素影响IBD的病因学，人类肠道中的微生物生态系统也是如此，它们并不均匀，而是代表了许多不同的微生境，这些微生境可能受到饮食的影响，并可能影响肠道代谢所必需的过程。关于肠道炎症的基础研究的进一步进展可能会揭示炎症介质（称为炎性体）和肠道细菌形成的代谢物大分子复合物的作用的新见解。总的来说，炎症小体和宏基因组学的知识将导致IBD生物标志物的发展，其靶向IBD自发进展中涉及的特定致病机制。在这篇综述文章中，介绍了我们最近关于使用无标记定量技术发现潜在蛋白质组学生物标志物的结果，以及正在进行的有助于IBD亚型区分或癌症风险预测的项目，并附有IBD生物标志物研究的最新信息。
Recent advances in genomic medicine have opened up the possibility of tailored medicine that may eventually replace traditional "one-size-fits all" approaches to the treatment of inflammatory bowel disease (IBD). In addition to exploring the interactions between hosts and microbes, referred to as the microbiome, a variety of strategies that can be tailored to an individual in the coming era of personalized medicine in the treatment of IBD are being investigated. These include prompt genomic screening of patients at risk of developing IBD, the utility of molecular discrimination of IBD subtypes among patients diagnosed with IBD, and the discovery of proteome biomarkers to diagnose or predict cancer risks. Host genetic factors influence the etiology of IBD, as do microbial ecosystems in the human bowel, which are not uniform, but instead represent many different microhabitats that can be influenced by diet and might affect processes essential to bowel metabolism. Further advances in basic research regarding intestinal inflammation may reveal new insights into the role of inflammatory mediators, referred to as the inflammasome, and the macromolecular complex of metabolites formed by intestinal bacteria. Collectively, knowledge of the inflammasome and metagenomics will lead to the development of biomarkers for IBD that target specific pathogenic mechanisms involved in the spontaneous progress of IBD. In this review article, our recent results regarding the discovery of potential proteomic biomarkers using a label-free quantification technique are introduced and on-going projects contributing to either the discrimination of IBD subtypes or to the prediction of cancer risks are accompanied by updated information from IBD biomarker research.